Epetraborole Is Active against Mycobacterium abscessus.

Area of Science:

• Medicinal Chemistry
• Microbiology
• Infectious Diseases

Background:

• Benzoxaboroles represent a novel class of leucyl-tRNA synthetase inhibitors.
• Previous research demonstrated the efficacy of 4-halogenated benzoxaboroles against Mycobacterium abscessus.
• There is a need for new therapeutic strategies to combat M. abscessus infections, particularly lung disease.

Purpose of the Study:

• To evaluate the activity of the nonhalogenated benzoxaborole epetraborole against Mycobacterium abscessus.
• To assess the efficacy of epetraborole in a preclinical mouse model of M. abscessus infection.

Main Methods:

• In vitro susceptibility testing of epetraborole against M. abscessus.
• In vivo efficacy study using a mouse model infected with M. abscessus.

Main Results:

• Epetraborole demonstrated significant antimicrobial activity against M. abscessus in vitro.
• Treatment with epetraborole resulted in reduced bacterial burden in a mouse model of M. abscessus infection.
• These findings confirm the potential of nonhalogenated benzoxaboroles as therapeutic agents.

Conclusions:

• Epetraborole is an active compound against Mycobacterium abscessus, expanding the utility of benzoxaboroles.
• This study identifies epetraborole as a promising lead compound for developing treatments for M. abscessus lung disease.
• The findings support further investigation of benzoxaborole derivatives for treating challenging bacterial infections.